£2.3m funding boost for new antibiotics

Funding | Healthcare | North West
A £2.3m funding package has been announced for the Antimicrobial Resistance (AMR) Centre.
The centre brings together public and private investors in the UK to tackle global health threats posed by antimicrobial resistance. The new funds will be put towards the development of new drugs to tackle ‘superbugs’, or drug-resistant infections. Backers include LifeArc, Bruntwood Sci-Tech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund.

The investment follows the announcement in January of the UK Government’s ‘National Action Plan’ to cut misuse of antibiotics. The plan sets out a 20-year vision for the control of AMR by 2040, covering health, animals, the environment, and the food chain.

The AMR Centre works with international SMEs and pharmaceutical companies to fast track potential new antibiotics into clinical trials.

Dr Peter Jackson, executive director of the AMR Centre, said: “We hope that this initial investment by LifeArc, combined with the continued support of our existing investors, will be the start of a fruitful collaboration on our shared mission to deliver new therapies for serious drug-resistant infections. There is currently a real momentum in the field of AMR research and investments like this are crucial in helping us build the collaborative networks we need to get life-saving drugs to market.”

The GM&C Life Sciences Fund is a seed and early-stage venture capital fund, which targets life sciences businesses, and is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *